psoriasis

July Clinical ConsiderationsIn this month's Clinical Considerations, we take a look at biologics and treatments for seborrheic keratoses.
Prescribing barriersDermatologists who plan to prescribe brodalumab may face a rough road.
Biologic class differentiatorsDermatology experts offer insight into differentiating factors among TNF-alpha inhibitors, the IL 12/23 antagonist, IL 17 inhibitors and an oral option that carry considerations for managing certain patients.
A peek at the pipelineThere is tremendous excitement surrounding IL-23 inhibitors for the treatment of psoriasis. Three are currently in the pipeline.
Paradoxical reactions to biologics provide insightParadoxical reactions to biologic treatments can provide clues into related conditions such as granulomatous diseases, genetic polymorphisms and latent infections, says an expert.
Pharmaceutical pipeline: Top 4 conditions to watch
Pharmaceutical pipeline: Top 4 conditions to watchAlthough drug spend is increasing for inflammatory conditions, diabetes, and oncology, there are some promising developments in the pipeline.
New systemic psoriasis treatments keep raising barBiologic inhibitors of IL-23 and IL-17 are commonly delivering responses of PASI 90 and above, says an expert.
Autoimmune drug pipeline: What health execs should watchNew drugs for RA, psoriasis, type 1 diabetes and Crohn’s disease—some recently approved and others coming down the pipeline—could have an impact on the industry.
A new class steps forwardPhosphodiesterase (PDE) inhibitors including apremilast and crisaborole ointment may provide safer alternatives than traditional steroid-sparing agents for psoriasis and atopic dermatitis. Side effects of apremilast may include GI symptoms, weight loss and depression, and taking apremilast with anti-seizure drugs or rifampin lowers apremilast blood levels, Apremilast is being studied in inflammatory bowel disease, Behcet's disease and pediatric psoriasis, and may have a place in the treatment of hidradenitis suppurativa (HS).
TNF inhibitor treatment tacticsWith a long history in dermatology and rheumatology, TNF inhibitors can not only improve psoriasis and psoriatic arthritis, but they also may reduce comorbid cardiovascular risks and work better combined with methotrexate. Low doses of cyclosporine may be effective at treating the psoriasis reaction when topicals have proven ineffective. Aggressively managing TNF-induced reactions can help patients stay on drugs that are working for other challenging diseases.